Australian-developed MND therapy advances to Phase 2 clinical trial
An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.
Read original article on The Medical News →Related news
-
Most eligible teens miss out on advanced obesity treatments
United Kingdom
-
AI analysis of ECG data measured by smartwatch may help detect reduced heart pumping function
United Kingdom
-
Complex procedure offers relief for children with chronic pancreatitis
United Kingdom
-
Phage protein study opens new path for future antibiotics
United Kingdom
-
DNA methylation patterns predict treatment response in MDS patients
United Kingdom
-
UCLA study identifies lipid imbalance as pulmonary fibrosis trigger
United Kingdom
-
Rutgers receives grant to explore drug overdose trends among youth
United Kingdom
-
Slow hands, quiet nights? Tai chi and a matched exercise class nudged sleep about equally in older men after cancer
United Kingdom